ImmunoCellular Therapeutics (IMUCD) Stock Price, News & Analysis

Company Overview

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for the treatment of aggressive cancers. The company’s core focus centers on dendritic cell-based vaccines designed to activate a patient’s immune system against tumor-associated antigens. By harnessing the body’s own defense mechanisms, ImmunoCellular aims to improve outcomes for patients with high-unmet-need malignancies, particularly glioblastoma multiforme (GBM).

The company’s lead product candidates include ICT-107 and ICT-121, both of which target specific antigens commonly expressed in GBM cells. ICT-107 is a personalized dendritic cell vaccine that has completed Phase 2 clinical trials, demonstrating a tolerable safety profile and preliminary signals of efficacy in newly diagnosed GBM patients. ICT-121 is being evaluated in early-phase studies for recurrent GBM, with the goal of extending survival and delaying disease progression. Beyond brain cancer, ImmunoCellular has also advanced ICT-140, an ovarian cancer vaccine candidate, into preclinical development, underscoring its broader commitment to cell-based oncology therapies.

Founded in the mid-2000s and headquartered in Los Angeles, California, ImmunoCellular Therapeutics operates primarily within the United States, collaborating with leading academic medical centers and research institutions. Its research and development efforts leverage partnerships to conduct multi-center clinical trials and to explore combination strategies with emerging immuno-oncology agents. The company’s scientific advisors comprise experts in neuro-oncology, immunology, and cell therapy, guiding its strategic direction and translational research initiatives.

Key Stats

• Today's Range: $0.09 to $0.09
• 50-Day Range: $0.07 to $0.10
• 52-Week Range: $0.16 to $0.51
• Volume: 2 shs
• Average Volume: 6,605 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMUCD Stock Analysis - Frequently Asked Questions

How have IMUCD shares performed this year?

ImmunoCellular Therapeutics' stock was trading at $0.1688 at the beginning of the year. Since then, IMUCD stock has decreased by 46.7% and is now trading at $0.09.

How do I buy shares of ImmunoCellular Therapeutics?

Shares of IMUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IMUCD
• CIK: N/A
• Web: www.imuc.com
• Phone: (818) 264-2300
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.63